news

Government letter advises pharma industry for no-deal Brexit

29
SHARES

The government has issued a letter to the pharmaceutical industry, outlining how to prepare for a no-deal Brexit.

A written ministerial statement and a letter were published yesterday afternoon by the UK government offering guidance to the pharmaceutical industry in the case of a ‘no deal’ Brexit. The letter explains that medicine supplies to the UK could be greatly affected by disrupted short straits.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The letter says that the “main risk to the unhindered supply of medicines and medical products presented by the UK exiting the EU without a deal remains the predicted reduced traffic flow at the short straits crossings.”

It also states that around three-quarters of medicines in the UK come from the EU and that “significant disruption,” is expected in the six months after a no-deal Brexit.

The buffers already in place include stockpiling, regulatory flexibility and a co-ordinated National Supply Disruption Response (NSDR) system to handle any issue which may arise. However, the government has set out even more steps for contingencies.

The letter addresses stakeholders within the industry, telling medicine suppliers to prepare by:

  • Planning routes to direct freight away from short straits
  • Stockpiling at six weeks above usual business levels
  • Preparing for new border controls.

The government has also taken steps to support re-routing:

  • The Department of Health and Social Care (DHSC) will begin a procuring ‘Express Freight Services’ to provide access to an end-to end solution able to deliver small consignments
  • The government will commence obtaining of ‘roll-on, roll-off’ freight capacity on which pharmaceuticals would be prioritised to ensure the flow of all these products may continue unimpeded.

Mike Thompson, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI) said: “Our members will be pleased that the government are taking steps to put this capacity in place again and await further information about how this will work in practice. However, it is extremely challenging for pharmaceutical companies to be continually preparing for a ‘no-deal’ Brexit. Leaving the EU with a deal in place remains the best way to minimise any potential disruption to medicines supplies.”

Share via
Share via